Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.
Klaus FranckeNiladri ChattopadhyayStefan KleinAntje RottmannDennis KrickauJeroen van de WeteringChristian FriedrichPublished in: European journal of drug metabolism and pharmacokinetics (2022)
Clinicaltrials.gov: NCT03773068 (initial registration: 12 December 2018).
Keyphrases